Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua A Roth

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Journal of Gastrointestinal Cancer|January 15, 2011
Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancerJoshua A Roth, Josh J Carlson
Clinical Lung Cancer|July 5, 2011
Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysisJoshua A Roth, Josh J Carlson
Breast Cancer Research and Treatment|August 27, 2013
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisJosh J Carlson, Joshua A Roth
JAMA|January 10, 2016
Computed Tomography Screening for Lung Cancer: A High-Value Proposition?Joshua A Roth, Scott D Ramsey
American Health & Drug Benefits|February 5, 2020
Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based TestingJoshua A Roth, Theo deVos, Scott D Ramsey
Journal of Medical Economics|March 4, 2025
Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in MedicareJoshua A Roth, David Kratochvil, Stephanie Dorman, et al.
The Oncologist|October 21, 2015
Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate CancerJoshua A Roth, Scott D Ramsey, Josh J Carlson
Journal of Medical Economics|April 6, 2026
Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicareJoshua A Roth, David Kratochvil, Kathryn Perkins, et al.
The American Journal of Managed Care|May 26, 2026
Biosimilar adoption and provider performance in Medicare value-based payment modelsBasit Chaudhry, Andrew Yue, Ahmed Shelbaya, et al.
The American Journal of Medicine|September 6, 2016
Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community SettingRagan Hart, David L Veenstra, Denise M Boudreau, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Journal of Gastrointestinal Cancer|January 15, 2011
Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancerJoshua A Roth, Josh J Carlson
Clinical Lung Cancer|July 5, 2011
Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysisJoshua A Roth, Josh J Carlson
Breast Cancer Research and Treatment|August 27, 2013
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisJosh J Carlson, Joshua A Roth
JAMA|January 10, 2016
Computed Tomography Screening for Lung Cancer: A High-Value Proposition?Joshua A Roth, Scott D Ramsey
American Health & Drug Benefits|February 5, 2020
Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based TestingJoshua A Roth, Theo deVos, Scott D Ramsey
Journal of Medical Economics|March 4, 2025
Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in MedicareJoshua A Roth, David Kratochvil, Stephanie Dorman, et al.
The Oncologist|October 21, 2015
Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate CancerJoshua A Roth, Scott D Ramsey, Josh J Carlson
Journal of Medical Economics|April 6, 2026
Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in medicareJoshua A Roth, David Kratochvil, Kathryn Perkins, et al.
The American Journal of Managed Care|May 26, 2026
Biosimilar adoption and provider performance in Medicare value-based payment modelsBasit Chaudhry, Andrew Yue, Ahmed Shelbaya, et al.
The American Journal of Medicine|September 6, 2016
Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community SettingRagan Hart, David L Veenstra, Denise M Boudreau, et al.
Pageof 6